Diagnostic Technologies Ltd.

Other

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Wayne State University

Semmelweis University

Genesis Theranostix Korlatolt Felelossegu Tarsasag

University of Iceland

Hananja Ehf

Gizurarson, Sveinbjorn

Meiri, Hamutal

Hamutal Meiri

Roberto Romero

Sveinbjorn Gizurarson

Adi L Tarca

Nandor Than

Gabor Juhasz

Adrienna Katalin Kekesi

Zoltan Papp

Adrienna Katalin KÉKESI

Zoltán Papp

Gábor JUHÁSZ

Nándor Than

Disclosed are specific biomarkers that allow for early testing of preeclampsia/HELLP syndrome. Thus, a method is provided predicting preeclampsia in a pregnant woman. Also disclosed is a kit comprising means for assaying a sample from a pregnant woman for the concentrations of the specific biomarkers.

Biomarker test for prediction or early detection of preeclampsia and/or HELLP syndrome

The present invention relates to the biological and pharmacological effects of placental protein 13 (PP-13), an effect that may be used as a treatment and/or prevention of preeclampsia and placental insufficiencies, in pregnant female mammals, especially pregnant women. The invention relates to a method to treat female mammals with the purpose to precondition the uterine arteries and prevent and/or reverse the pathological conditions associated with placental insufficiency such as preeclampsia, HELLP and/or eclampsia.

Biological activity of placental protein 13

A method of monitoring tocolytic therapy in a pregnant woman. The method comprises determining a first concentration of placental protein 13 (PP13) in a bodily substance of a woman who has not received treatment with a tocolytic agent, determining a second concentration of PP13 in a bodily substance of the pregnant woman after initiation of treatment with a tocolytic agent, and comparing the second concentration with the first concentration. Based on the comparison, it may be determined whether to continue, discontinue, or modify the tocolytic treatment.

Method for monitoring tocolytic treatment

A method for diagnosing pregnancy-related complications in a pregnant woman. The method comprises (a) providing PP13-responding cells having a membrane; (b) exposing the cells to standard PP13; (c) exposing PP13-responding cells to PP13 obtained from the woman, and (d) determining the existence of a modification in the permeability of the cell membrane in (b) and in (c) as a result of exposure to PP13. The modification in permeability in (b) and (c) is then compared, a change in the permeability of (c) as compared to the permeability in (b) indicating the existence of a pregnancy complication in the woman.

Method of diagnosis of pregnancy-related complications

Growing community of inventors

Tel Aviv, Israel

Hamutal Meiri